bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.01.13.698512

Characterising the detectable and invisible fractions of genomic loci under balancing selection

Abstract

Balancing selection refers to scenarios where selection maintains genetic polymorphisms affecting fitness and its components. Empirical studies have documented specific cases of balancing selection, yet the general prevalence of balanced polymorphisms within genomes remains a topic of longstanding debate. Although genome-wide scans for signals of balancing selection suggest that it is rare, current methods are notoriously conservative and may identify only a small and unrepresentative fraction of loci evolving under balancing selection. What, then, are the proportions of loci under balancing selection that are detectable versus invisible to genome scans? Here, we address this question using a combination of analytical modelling and population genetic simulations. Our results provide quantitative support for the intuition that a large fraction of loci under balancing selection will be invisible to standard tests for balancing selection, with the detectable loci representing a biased subset with large and symmetrical fitness effects on different fitness components. Quantifying power across parameters that vary between species also shows that the detectable and invisible fractions of genomic loci under balancing selection are likely to differ substantially between organisms. For example, a Drosophila melanogaster-like ratio of mutation to recombination rates ([~]0.1) reduces detection power by roughly a quarter of the power expected with a human-like ratio ([~]1). This, combined with other evidence suggesting that balancing selection could be common in D. melanogaster, showcases how our appreciation of the prevalence of balancing selection is limited by our ability to detect its genomic signals, especially in those species where it might be common.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Yoshihara Caldeira Brandt, D., Andres, A. M., Connallon, T., Reuter, M.. 2026-01-13. Characterising the detectable and invisible fractions of genomic loci under balancing selection. https://doi.org/10.64898/2026.01.13.698512

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

OPA1 controls mitochondrial dysfunction-driven liver fibrosis in MASLD

Progressive hepatic fibrosis is the principal determinant of morbidity and mortality in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). Mitochondrial dysfunction is a hallmark of MASH, and the release of mitochondrial damage-associated molecular patterns (mito-DAMPs) from injured hepatocytes can promote fibrosis. However, how mitochondrial dynamics and quality control shape the fibrotic response in MASLD/MASH remains unclear. Here, through large-scale genomic analyses of mitochondrial genes governing mitophagy, fusion and fission in human MASLD, with a power-equivalent sample size of approximately 700,000 individuals, we identify a strong association between hepatic fibrosis and the mitochondrial fusion factor dynamin-like GTPase optic atrophy 1 (OPA1). OPA1 transcripts and protein abundance in the liver epithelium were progressively dysregulated with advancing fibrosis. In mice, hepatocyte-specific OPA1 loss alone was sufficient to induce hepatic stellate cell activation and fibrosis in zone 3, promoted the release of mito-DAMPs into the circulation and exacerbated fibrosis in experimental MASH. These findings identify OPA1 as a central regulator of the hepatic fibrotic response and connect defective mitochondrial homeostasis to mito-DAMP release, hepatic stellate cell activation and fibrosis in MASLD.

genetics↗

Mechanism-selective deep mutational scanning distinguishes ERCC2 disease phenotypes

Pathogenic ERCC2 variants cause xeroderma pigmentosum (XP), trichothiodystrophy (TTD) or both, yet variant effect scores are usually interpreted only as measures of pathogenicity rather than of which disease mechanism is disrupted. XPD, the ERCC2-encoded TFIIH subunit, functions in both nucleotide excision repair and transcription. Using yeast complementation deep mutational scanning, we measured the effects of nearly all XPD amino acid substitutions. The assay was mechanism-selective: it preferentially reported transcription-associated function, with pronounced intolerance at the p44 interface, whereas many substitutions affecting DNA binding and helicase activity retained near-wild-type fitness. Accordingly, TTD variants had much lower fitness than XP variants. Computational predictors discriminated pathogenic from benign variants similarly across phenotypes, but the DMS distinguished XP from TTD variants better than all 73 predictors tested. Phenotype-specific ACMG/AMP calibration provided evidence in both directions for TTD but mainly pathogenic evidence for XP. Thus, the selectivity of functional assays, often viewed as a limitation, can reveal disease mechanisms and support phenotype-aware variant interpretation.

genetics↗

Temporal control of mitochondrial mutagenesis reveals the fate of mtDNA mutations with age

Mutations in the mitochondrial genome (mtDNA) play a critical role in the aging process and a wide variety of age-related diseases. However, it remains unclear when the mutations that drive physiological decline arise. To answer this question, we generated a new mouse model in which mitochondrial mutagenesis can be confined to a defined window of time. Surprisingly, we found that mutations that arise during the first two months of life are sufficient to drive a wide variety of age-related pathologies, and that the severity of this pathology is broadly regulated by distinct, tissue-specific selective pressures that control the fate of mtDNA mutations with age. Further, we found that selection against deleterious variants can be modulated by manipulation of mitochondrial fusion in vitro and in vivo. These observations raise the possibility that in some tissues, the pace of aging is pre-determined by events that occur early in life and that interventions targeting mitochondrial fusion may be able to slow down or reverse the expansion of these pathogenic variants. These results carry far-reaching implications for strategies aimed at preventing or delaying age-related decline.

genetics↗